WallStSmart
RLMD

Relmada Therapeutics Inc

NASDAQ: RLMD · HEALTHCARE · BIOTECHNOLOGY

$7.52
+2.04% today

Updated 2026-04-30

Market cap
$759.40M
P/E ratio
P/S ratio
9,001.90x
EPS (TTM)
$-1.45
Dividend yield
52W range
$0 – $8
Volume
2.1M

Relmada Therapeutics Inc (RLMD) Financial statements

SEC filings — annual and quarterly data.

Income statement — annual

Item20122013201420152016201720182019202020212022202320242025
Revenue$7941.00$5129.00$0.00$0.00$0.00$0.00$0.00$0.00$0.00
Revenue growth (YoY)-35.4%-100.0%
Cost of revenue$5799.00$4036.00$9256.00$54819.00$85271.00$2627.00$4870.00$3752.00$1258.00
Gross profit$2142.00$1093.00$-9256.00$-54819.00$-85271.00$-2627.00$-4870.00$-3752.00$-1258.00
Gross margin27.0%21.3%
R&D$5.38M$7.87M$7.87M$6.21M$1.29M$2.94M$7.86M$35.97M$90.62M$113.32M$54.81M$46.18M$744560.00
SG&A$9090.00$45076.00$9.23M$9.23M$10.01M$5.93M$3.98M$7.25M$24.87M$35.08M$47.93M$48.90M$37.72M$311904.00
Operating income$-12052.00$-45015.00$-17.10M$-17.10M$-16.22M$-7.22M$-6.92M$-15.11M$-60.84M$-125.70M$-161.25M$-103.70M$-83.89M$-59.10M
Operating margin-151.8%-877.7%
EBITDA$-11675.00$-45015.00$-20.79M$-17.09M$-16.03M$-6.92M$-6.92M$-15.11M$-59.33M$-125.70M$-161.25M$4.91M$-83.89M$-59.10M
EBITDA margin-147.0%-877.7%
EBIT$-12429.00$-45388.00$-20.80M$-17.10M$-16.08M$-7.01M$-6.92M$-15.11M$-59.34M$-125.70M$-161.25M$-98.79M$-79.98M
Interest expense$4922.00$4922.00$550.00$1.34M$1.40M$48317.00$4.21M
Income tax$-377.00$-9.58M$3.70M$-13.11M$-716000.00$2.05M$4.59M$-1.38M$48317.00$-2.66M$-103702.00
Effective tax rate3.0%99.5%0.0%-21.7%81.5%10.2%-29.6%-44.1%2.3%-0.0%1.7%0.1%0.0%0.0%
Net income$-12052.00$-45015.00$-20.80M$-20.80M$-2.98M$-6.29M$-8.96M$-15.01M$-59.46M$-125.75M$-157.04M$-98.79M$-79.98M$-57.39M
Net income growth (YoY)-273.5%-46114.8%-0.0%+85.7%-111.3%-42.5%-67.4%-296.2%-111.5%-24.9%+37.1%+19.0%+28.3%
Profit margin-151.8%-877.7%